We proposed that stimulating IFN signaling with STINGa may be a good strategy to compensate for defective innate immune signaling in Herceptin-resistant HER2+ BC and have a synergistic anti-tumor effect with DS-8201. This evidence concerns the gene IFNA1 and breast cancer.